IAMA-004

N/A

Report date: 2024/07/12 11:59:40

Base Information

Drug NameIAMA-004
Drug Alias NameIAMA-004ISE-Tri-Ab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-HER2Anti-Cluster of differentiation 47Anti-Low affinity immunoglobulin gamma Fc region receptor III-A
TargetsReceptor protein-tyrosine kinase erbB-2Cluster of differentiation 47Low affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Jsiama Biopharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Jsiama Biopharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A